Chalfont St Giles, UK and Philadelphia, PA – General Electric and MDS Pharma Services announced the availability of a new, automated in vitro micronucleus assay that incorporates GE Healthcare’s IN Cell 1000 and IN Cell 3000 high content analysis platforms. This automated imaging assay enables an accurate, early assessment of the potential genotoxicity of novel drug candidates in early drug discovery and development.

The assay protocol developed by MDS Pharma Services and GE Healthcare provides enhanced sensitivity and concurrent toxicity data to help more accurately interpret micronuclei formation. The fully automated assay format allows for faster data collection and analysis, in addition to providing greater research flexibility with respect to customization of additional multiplexed end-points.